Smartlab Europe

Drug Research

Titan Pharmaceuticals Receives Fda Communication On Ropinirole Implant Investigational New Drug Application

Titan Pharmaceuticals, Inc ,a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform announced that the U.S. FDA has completed its initial review of the ropinirole implant Investigational New...

Sanofi and Regeneron Announce First  Approval of KevzaraTM for the Treatment of Moderately

Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody. For the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate...

Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre

University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes....

IBM Watson Health and Lundbeck form collaboration on technology for developing innovative medicine

H. Lundbeck A/S is collaborating with IBM's Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck's expertise in the treatment of psychiatric and neurological disorders...

PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases

PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune's current investors include Novartis Venture...

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma

Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Under the terms of...

Maverick Therapeutics, Takeda pharma  join to drive T-cell Engagement therapeutics for cancer 

Maverick Therapeutics Inc , an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited announced that they have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »